HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hiroji Iwata Selected Research

Cyclin-Dependent Kinase 4

1/2022AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer.
12/2021Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data.
1/2021Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
1/2021Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
1/2019Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
11/2018Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
1/2017Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hiroji Iwata Research Topics

Disease

230Breast Neoplasms (Breast Cancer)
10/2022 - 01/2002
80Neoplasms (Cancer)
07/2022 - 01/2002
23Neoplasm Metastasis (Metastasis)
07/2020 - 10/2002
22Neutropenia
10/2022 - 08/2008
14Disease Progression
09/2022 - 01/2007
13Triple Negative Breast Neoplasms
11/2021 - 12/2012
7Diarrhea
09/2021 - 03/2015
6Fatigue
10/2022 - 07/2015
6Nausea
11/2021 - 10/2007
6Leukopenia
09/2021 - 08/2008
5Vomiting
01/2021 - 10/2007
5Febrile Neutropenia
01/2020 - 10/2007
5Stomatitis
12/2019 - 11/2014
5Brain Neoplasms (Brain Tumor)
11/2017 - 08/2013
5Carcinoma (Carcinomatosis)
01/2017 - 10/2002
4Thrombocytopenia (Thrombopenia)
08/2022 - 01/2015
4Interstitial Lung Diseases (Interstitial Lung Disease)
06/2022 - 01/2020
4Anemia
01/2021 - 11/2014
4Stomach Neoplasms (Stomach Cancer)
01/2020 - 04/2002
4Carcinogenesis
10/2019 - 02/2003
4Hand-Foot Syndrome
11/2018 - 10/2010
4Ductal Carcinoma
09/2018 - 06/2006
4Edema (Dropsy)
03/2017 - 01/2005
3Pneumonia (Pneumonitis)
01/2022 - 08/2020
3Peripheral Nervous System Diseases (PNS Diseases)
01/2022 - 01/2020
3Lymphatic Metastasis
10/2021 - 11/2002
3Noninfiltrating Intraductal Carcinoma (DCIS)
03/2021 - 08/2017
3Alopecia (Baldness)
11/2020 - 12/2015
3Pathologic Complete Response
11/2019 - 04/2011
3Exanthema (Rash)
01/2019 - 01/2015
3Hyperglycemia
01/2019 - 11/2014
3Circulating Neoplastic Cells
01/2018 - 01/2014

Drug/Important Bio-Agent (IBA)

57Hormones (Hormone)IBA
10/2022 - 01/2002
38Trastuzumab (Herceptin)FDA Link
09/2022 - 10/2005
35Estrogen ReceptorsIBA
01/2022 - 10/2002
27ErbB Receptors (EGF Receptor)IBA
10/2022 - 05/2011
23human ERBB2 proteinIBA
09/2022 - 10/2008
20palbociclibIBA
10/2022 - 07/2015
16Aromatase InhibitorsIBA
01/2022 - 06/2010
16Fulvestrant (Faslodex)FDA Link
01/2022 - 12/2013
15Paclitaxel (Taxol)FDA LinkGeneric
01/2022 - 01/2009
14Docetaxel (Taxotere)FDA Link
08/2021 - 01/2005
14Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2020 - 02/2004
12Pharmaceutical PreparationsIBA
06/2022 - 01/2006
10exemestane (Aromasin)FDA Link
11/2021 - 04/2011
10Capecitabine (Xeloda)FDA Link
11/2018 - 02/2004
10TamoxifenFDA LinkGeneric
12/2014 - 07/2003
9taxaneIBA
01/2022 - 11/2009
9Progesterone Receptors (Progesterone Receptor)IBA
10/2021 - 07/2003
9AnthracyclinesIBA
10/2020 - 11/2009
8Ado-Trastuzumab EmtansineIBA
09/2022 - 01/2015
8trastuzumab deruxtecanIBA
03/2022 - 01/2019
8Letrozole (Femara)FDA LinkGeneric
01/2022 - 04/2011
8130-nm albumin-bound paclitaxelIBA
11/2021 - 05/2017
8atezolizumabIBA
11/2021 - 11/2018
8Phenobarbital (Luminal)FDA Link
09/2021 - 04/2011
8Biomarkers (Surrogate Marker)IBA
03/2021 - 07/2007
8Anastrozole (Arimidex)FDA LinkGeneric
11/2014 - 06/2010
7Cyclin-Dependent Kinase 4IBA
01/2022 - 01/2017
7Lapatinib (GW572016)FDA Link
08/2021 - 08/2013
7Fluorouracil (Carac)FDA LinkGeneric
04/2020 - 01/2005
7Epirubicin (Ellence)FDA LinkGeneric
04/2020 - 02/2004
6pertuzumabIBA
09/2022 - 05/2018
6Proteins (Proteins, Gene)FDA Link
08/2022 - 02/2007
6abemaciclibIBA
08/2022 - 01/2019
5Bevacizumab (Avastin)FDA Link
06/2022 - 10/2011
5Tyrosine Kinase InhibitorsIBA
01/2021 - 08/2013
5neratinibIBA
01/2021 - 03/2016
5eribulinFDA Link
01/2018 - 06/2013
4Biological ProductsIBA
03/2022 - 01/2002
4B7-H1 AntigenIBA
11/2021 - 11/2018
4Epidermal Growth Factor (EGF)IBA
08/2021 - 05/2010
4GemcitabineFDA Link
12/2020 - 11/2009
4Monoclonal AntibodiesIBA
01/2020 - 10/2005
4EverolimusFDA Link
10/2019 - 05/2013
4EnzymesIBA
11/2014 - 04/2002
4ORALIT (ORS)IBA
02/2011 - 04/2002
3Immunoconjugates (Immunoconjugate)IBA
01/2022 - 01/2015
3TeaIBA
01/2022 - 08/2021
3Immune Checkpoint InhibitorsIBA
03/2021 - 11/2017
3Albumin-Bound PaclitaxelFDA Link
03/2021 - 04/2015
3Carboplatin (JM8)FDA LinkGeneric
12/2020 - 06/2014
3Estrogens (Estrogen)FDA Link
10/2019 - 04/2016
3Doxorubicin (Adriamycin)FDA LinkGeneric
01/2018 - 09/2014
3Goserelin (Zoladex)FDA Link
01/2017 - 04/2012
3thiamine triphosphorate (TTP)IBA
03/2015 - 02/2010
3Codon (Codons)IBA
01/2007 - 01/2003

Therapy/Procedure

98Therapeutics
10/2022 - 07/2003
51Drug Therapy (Chemotherapy)
09/2022 - 01/2005
19Neoadjuvant Therapy
07/2022 - 01/2005
16Adjuvant Chemotherapy
03/2022 - 10/2005
13Radiotherapy
07/2021 - 09/2007
7Lymph Node Excision (Lymph Node Dissection)
07/2020 - 11/2002
7Segmental Mastectomy (Lumpectomy)
07/2020 - 01/2005
5Mastectomy (Mammectomy)
08/2021 - 09/2018
4Drug Tapering
08/2022 - 10/2016
4Mammaplasty (Breast Reconstruction)
08/2021 - 09/2018
3Operative Surgical Procedures
05/2019 - 05/2017
3Duration of Therapy
01/2019 - 01/2007
2Retreatment
09/2022 - 09/2018